Lignans' potential in pre- and post-onset type 2 diabetes management.
Type 2 diabetes (T2D) cases continue to rise dramatically despite efforts to get people to exercise and eat with a view to health and combatting the cluster of 7 issues (elevated waist circumference, hyperglycaemia, hypertension, dyslipidemia, pro-thrombotic state, increased oxidation (including low density lipoprotein (LDL)) and the pro-inflammatory state associated with pre- and post-onset T2D. There are numerous medications available to deal with these seven major issues. However, each medication currently available manages a maximum of two cluster members at a time. Consequently, polypharmacy is frequently required to manage the cluster of seven. Polypharmacy brings with it high financial costs for numerous medications, the risk of poor compliance (particularly so in older patients), side effects and drug interactions. Thus, there is a search for new agents that reduce the high costs and risks of polypharmacy while at the same time combatting three or more of the cluster of seven. There is very limited evidence to suggest that one or more lignans may efficaciously and safely, in the short and long term, manage at least three of the cluster of seven, pre- and post-T2D onset, thus reducing polypharmacy. However, multi-centre, large, clinical trials are required before any definitive conclusions about these lignans can be reached regarding its safe and efficacious polypharmacy reduction potential, both long and short term, in pre- and post-onset T2D management. It is concluded that some lignans appear to have the potential to manage at least three members of the cluster of seven in pre- or post-T2D onset and hence reduce polypharmacy but much more investigation is required to confirm if such is the case. At the moment there is not enough evidence that any of the lignans will, in the long or short term, safely and efficaciously manage the cluster of seven via polypharmacy reduction.